Therapy Detail

Therapy Name Golvatinib
Synonym
Therapy Description

Golvatinib (E7050) is a dual kinase inhibitor of c-Met and KDR (VEGFR2), which inhibits cell growth and proliferation (PMID: 25458359).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Golvatinib E7050 EPHB4 Inhibitor 6 MET Inhibitor 51 VEGFR2 Inhibitor 34 Golvatinib (E7050) is a dual kinase inhibitor of c-Met and KDR (VEGFR2), which inhibits cell growth and proliferation (PMID: 25458359).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown pancreatic cancer not applicable Golvatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Golvatinib (E7050) inhibited tumor angiogenesis and tumor growth in xenografts of a VEGF-overexpressing human pancreatic cancer cell line (PMID: 19832844). 19832844
MET amp lung cancer sensitive Golvatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844). 19832844
MET amp stomach cancer sensitive Golvatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of gastric cancer cell lines in culture and in cell line xenograft models (PMID: 19832844). 19832844
Unknown unknown Advanced Solid Tumor not applicable Golvatinib Phase I Actionable In a Phase I trial, Golvatinib (E7050) demonstrated safety and preliminary efficacy, with stable disease as best overall response in patients with advanced solid tumors (PMID: 25278451). 25278451
Clinical Trial Phase Therapies Title Recruitment Status
NCT01433991 Phase Ib/II Golvatinib Lenvatinib E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) Unknown status